Signature genetic lesions in GBM include amplification, mutation, and/or overexpression of receptor tyrosine kinases (RTKs), such as EGFR and PDGFRα, as well as activating mutations in components of the PI-3 kinase (PI3K) pathway (reviewed in [1]). This evidence concerns the gene NTRK1 and glioblastoma.